14 recruiting, 7 not yet recruiting, 4 completed, 3 terminated. 28 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Recruiting 14, Not yet recruiting 7, Completed 4, Terminated 3 |
| Phase 2 | 5 | Not yet recruiting 3, Recruiting 2 |
Follow Solid Tumor Malignancies: new trials by email Literature Review of Solid Tumor Malignancies trials Research Report on Solid Tumor Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors SND002 Cell Injection - Colorectal Neoplasms, Stomach Neoplasms | Phase 1 | Not yet recruiting | Guizhou Sinorda Pharmaceutical Co., Ltd. | 78 | 2026-12-01 | 2026-10-29 |
| GKL-006Allo Injection in Patients With Advanced Solid Tumors GKL-006Allo Injection - Solid Tumor Malignancies | Phase 1 | Not yet recruiting | Beijing Gene Key Life Technology Co., Ltd | 27 | 2026-08-30 | 2026-07-15 |
| A Clinical Study of GO321 in Patients With Advanced Solid Tumors GO321 - Solid Tumor Malignancies | Phase 1 | Not yet recruiting | GeneSail Biotech (Shanghai) Co., Ltd. | 21 | 2026-08-15 | 2026-08-05 |
| A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors FG-B901, FG-M108 - Claudin 18.2, Solid Tumor Malignancies | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 120 | 2026-07-30 | 2026-07-15 |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) Pedmark® STS - Solid Tumor Malignancies, Testicular Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 25 | 2026-05-18 | 2026-06-18 |
| Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors TYK-01054 - Solid Tumor Malignancies, Malignant Mesothelioma (MM) | Phase 1 / Phase 2 | Not yet recruiting | TYK Medicines, Inc | 219 | 2026-01-01 | 2025-12-22 |
| A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia SXRN Injection - Cachexia-Anorexia Syndrome, Solid Tumor Malignancies | Phase 1 | Recruiting | Jiangsu Nutai Biologics Co., Ltd | 54 | 2025-11-17 | 2025-12-08 |
| 68Ga-GP-01 Injection in Solid Tumors Participants 68Ga-GP-01 Injection - Solid Tumor Malignancies | Phase 1 | Not yet recruiting | GrandPharma (China) Co., Ltd. | 20 | 2025-10-31 | 2025-07-03 |
| A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies KQB548 - Solid Tumor Malignancies | Phase 1 | Recruiting | Kumquat Biosciences Inc. | 78 | 2025-09-16 | 2026-05-20 |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors CP-383 - Solid Tumor Malignancies, Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Tasca Therapeutics | 150 | 2025-08-27 | 2026-02-18 |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors TJ101 - Lung Cancer (NSCLC), Prostate Cancer | Phase 1 | Recruiting | Phrontline Biopharma | 200 | 2025-08-25 | 2026-01-12 |
| A Clinical Study of GO306 in Patients With Advanced Solid Tumors GO306 - Solid Tumor Malignancies | Phase 1 | Recruiting | GeneSail Biotech (Shanghai) Co., Ltd. | 32 | 2025-07-31 | 2025-12-19 |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors VIR-5525, Pembrolizumab - Solid Tumor Malignancies, EGFR Positive Solid Tumors | Phase 1 | Recruiting | Vir Biotechnology, Inc. | 450 | 2025-07-22 | 2026-04-13 |
| A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors DC50292A - Solid Tumor Malignancies | Phase 1 | Recruiting | Heronova Pharmaceuticals | 32 | 2025-06-30 | 2026-09-16 |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB168, Pembrolizumab - Solid Tumor Malignancies | Phase 1 | Recruiting | Kumquat Biosciences Inc. | 84 | 2025-06-24 | 2026-03-03 |
| A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors SWA1211 - Solid Tumor Malignancies | Phase 1 | Recruiting | Beijing StoneWise Technology Co., Ltd | 60 | 2025-06-13 | 2026-01-23 |
| A Study of SH009 Injection in Patients With Advanced Solid Tumors. SH009 - Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC) | Phase 1 | Recruiting | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 150 | 2025-05-16 | 2026-02-05 |
| A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB365, Cetuximab, KQB198 - KRAS G12C Mutation, KRAS G12S Mutation | Phase 1 | Recruiting | Kumquat Biosciences Inc. | 140 | 2025-02-04 | 2026-04-23 |
Showing 20 of 28. Sign in to see all of them.
Neoplasm Metastasis (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Esophageal Neoplasms (2) · Hypoxia (2) · Lung Neoplasms (2) · Necrosis (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Chordoma (1) · Head and Neck Neoplasms (1) · Hearing Loss (1)
Neoplasms (9) · Neoplasms by Site (9) · Digestive System Diseases (6) · Gastrointestinal Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Digestive System Neoplasms (5) · Gastrointestinal Neoplasms (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Lung Diseases (4) · Male Urogenital Diseases (4) · Neoplastic Processes (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4)
Bacterial Load (2) · pembrolizumab (2) · Cetuximab (1) · Magnetic Resonance Spectroscopy (1) · STA 9090 (1) · Valproic Acid (1) · imetelstat (1) · vadimezan (1)
Kumquat Biosciences Inc. (3) · BioMed Valley Discoveries, Inc (2) · GeneSail Biotech (Shanghai) Co., Ltd. (2) · A2A Pharmaceuticals Inc. (1) · Beijing Gene Key Life Technology Co., Ltd (1) · Beijing StoneWise Technology Co., Ltd (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · Geron Corporation (1) · GrandPharma (China) Co., Ltd. (1) · Guizhou Sinorda Pharmaceutical Co., Ltd. (1) · Heronova Pharmaceuticals (1) · Jiangsu Nutai Biologics Co., Ltd (1) · Nanjing Sanhome Pharmaceutical, Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Phrontline Biopharma (1)
United States (16) · China (11) · Australia (1)
Alejandro Recio-Boiles, MD (1) · Anish Thomas, MBBS, MD (1) · David Nanus, M.D. (1) · Lisa Davis, PharmD (1) · Ning Li, MD (1) · Robert Flavell, MD (1)
2023 (1), R42CA217482 (1)